PMID- 33334146
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20230322
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Print)
IS  - 1479-1641 (Linking)
VI  - 17
IP  - 6
DP  - 2020 Nov-Dec
TI  - Maturity onset diabetes of the young and fibrin-related thrombosis risk.
PG  - 1479164120963048
LID - 10.1177/1479164120963048 [doi]
LID - 1479164120963048
AB  - BACKGROUND: Fibrin network characteristics determine predisposition to 
      cardiovascular disease (CVD). Individuals with type 1 (T1DM) and type 2 diabetes 
      mellitus (T2DM) have higher risk of CVD and display deranged fibrin network 
      structure. Those with maturity onset diabetes of the young (MODY) may also be at 
      increased risk but their fibrin clot properties have not been studied. METHODS: 
      Plasma clots properties from 13 individuals with HNF1A-MODY, 12 
      matched-individuals with T2DM and 12 with T1DM were studied using a validated 
      turbidimetric assay and confocal microscopy. Plasma levels of fibrinogen, 
      plasminogen activator inhibitor-1, complement C3 and C-reactive protein were also 
      measured. RESULTS: MODY clot maximum absorbance was 0.37 +/- 0.03 AU, similar to 
      T1DM (0.32 +/- 0.03 AU; p = 0.26), but lower than T2DM (0.49 +/- 0.03 AU; p = 0.02), 
      with confocal microscopy confirming structural differences. Clot lysis time in 
      MODY was similar to T1DM (456 +/- 50 and 402 +/- 20 s, respectively; p = 0.09) but 
      shorter than T2DM (588 +/- 58 s; p = 0.006). Comparing inflammatory/thrombotic 
      proteins in HNF1A-MODY and T2DM, C3 levels were lower in MODY than T2DM 
      (0.58 +/- 0.09 and 0.80 +/- 0.1 mg/ml, respectively; p < 0.01). CONCLUSIONS: 
      HNF1A-MODY fibrin network alterations are at least as pronounced as in T1DM but 
      less thrombotic than T2DM clots. Differences in fibrin clot characteristics 
      comparing HNF1A-MODY and T2DM may, in part, relate to lower C3 levels.
FAU - Sagar, R C
AU  - Sagar RC
AUID- ORCID: 0000-0001-7972-3321
AD  - Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and 
      Health, University of Leeds, Leeds, West Yorkshire, UK.
FAU - Phoenix, F
AU  - Phoenix F
AD  - Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and 
      Health, University of Leeds, Leeds, West Yorkshire, UK.
FAU - Thanabalasingham, G
AU  - Thanabalasingham G
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, 
      Oxford, UK.
FAU - Naseem, K
AU  - Naseem K
AD  - Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and 
      Health, University of Leeds, Leeds, West Yorkshire, UK.
FAU - Ajjan, R A
AU  - Ajjan RA
AD  - Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and 
      Health, University of Leeds, Leeds, West Yorkshire, UK.
FAU - Owen, K R
AU  - Owen KR
AD  - Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, 
      Oxford, UK.
AD  - Oxford NIHR Biomedical Research Centre, Churchill Hospital, Oxford, UK.
LA  - eng
GR  - FS/19/45/34443/BHF_/British Heart Foundation/United Kingdom
PT  - Journal Article
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Biomarkers)
RN  - 0 (C3 protein, human)
RN  - 0 (Complement C3)
RN  - 0 (HNF1A protein, human)
RN  - 0 (Hepatocyte Nuclear Factor 1-alpha)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - 0 (SERPINE1 protein, human)
RN  - 9001-31-4 (Fibrin)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - Mason-Type Diabetes
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - C-Reactive Protein/analysis
MH  - Complement C3/analysis
MH  - Diabetes Mellitus, Type 2/blood/*complications/diagnosis/genetics
MH  - Female
MH  - Fibrin/*analysis
MH  - Genetic Predisposition to Disease
MH  - Hepatocyte Nuclear Factor 1-alpha/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Plasminogen Activator Inhibitor 1/blood
MH  - Risk Factors
MH  - Thrombosis/blood/diagnosis/*etiology
MH  - Young Adult
PMC - PMC7919224
OTO - NOTNLM
OT  - MODY
OT  - clot structure
OT  - fibrinolysis
OT  - thrombosis
COIS- Declaration of conflicting interests: The author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: RCS: Nil; FP: Nil; GT: Nil; KN: Nil; KAO: Nil; RAA: 
      Institutional Research Grants from Abbott, Bayer, Eli Lilly, NovoNordisk, Roche, 
      Takeda as well as honoraria/education support/Consultancy from Abbott, 
      AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, 
      GlaxoSmithKline, Merck Sharp & Dohme, NovoNordisk and Takeda.
EDAT- 2020/12/19 06:00
MHDA- 2021/01/26 06:00
PMCR- 2020/12/18
CRDT- 2020/12/18 05:27
PHST- 2020/12/18 05:27 [entrez]
PHST- 2020/12/19 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2020/12/18 00:00 [pmc-release]
AID - 10.1177_1479164120963048 [pii]
AID - 10.1177/1479164120963048 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120963048. doi: 
      10.1177/1479164120963048.